The stock of psychedelics company Mind Medicine Inc.
rose 4% Friday, after the company’s Swiss research partners reported positive results from a Phase 2 trial of LSD as a treatment for major depressive disorder, or MDD. The trial involving 61 patients showed “rapid, durable and beneficial effects” of LSD in mitigating the symptoms of MDD, the company said in a statement. The high dose regimen involved giving patients 100 ug on the first dosing day, followed four weeks later by a 200 ug dose.
rose 4% Friday, after the company’s Swiss research partners reported positive results from a Phase 2 trial of LSD as a treatment for major depressive disorder, or MDD. The trial involving 61 patients showed “rapid, durable and beneficial effects” of LSD in mitigating the symptoms of MDD, the company said in a statement. The high dose regimen involved giving patients 100 ug on the first dosing day, followed four weeks later by a 200 ug dose.